Overview

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Status:
Active, not recruiting

Trial end date:
2023-08-02

Target enrollment:

Participant gender:

Summary

This phase I/II trial studies side effects and best dose of copanlisib when given together with letrozole and palbociclib and to see how well they work in treating hormone receptor positive HER2 negative stage I-IV breast cancer. Copanlisib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs, such as letrozole, may lessen the amount of estrogen made by the body. Giving copanlisib, letrozole, and palbociclib may work better in treating patients with breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Jonsson Comprehensive Cancer Center

Collaborators:

Bayer
National Cancer Institute (NCI)
Translational Research in Oncology-U.S. Inc. (TRIO-US)

Treatments:

Hormones
Letrozole
Palbociclib